Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression

Molecular and Cellular Endocrinology

Volumn 413, Issue , 2015, Pages 49-60

  Hirukawa, Hidenori ^a   Kaneto, Hideaki ^a   Shimoda, Masashi ^a   Kimura, Tomohiko ^a   Okauchi, Seizo ^a   Obata, Atsushi ^a   Kohara, Kenji ^a   Hamamoto, Sumiko ^a   Tawaramoto, Kazuhito ^a   Hashiramoto, Mitsuru ^b   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b YODOGAWA CHRISTIAN HOSPITAL   (Japan)

Author keywords

Cellular kinetics; DPP 4 inhibitor; Pancreatic cells; Thiazolidine derivative

Indexed keywords

ADIPONECTIN; ALOGLIPTIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, MOUSE; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIPERIDINE DERIVATIVE; URACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DIABETES MELLITUS, EXPERIMENTAL; METABOLISM; PATHOLOGY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL PEPTIDASE 4; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-SECRETING CELLS; MALE; MICE; PIPERIDINES; PPAR GAMMA; THIAZOLIDINEDIONES; URACIL;

EID: 84938292971     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.06.010     Document Type: Article

References (39)

1. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., Fujitani Y., Hirose T., Kawamori R., Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
2. Beltowski J., Rachanczyk J., Wlodarczyk M. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res. 2013, 628628:1-8.
3. Campbell I.W., Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res. Clin. Pract. 2007, 76:163-176.
4. Costes S., Broca C., Bertrand G., Lajoix A.D., Bataille D., Bockaert J., Dalle S. ERK1/2 control phosphorylation and protein level of cAMP-responsive element-binding protein: a key role in glucose-mediated pancreatic beta-cell survival. Diabetes 2006, 55:2220-2230.
5. Dalle S., Quoyer J., Varin E., Costes S. Roles and regulation of the transcription factor CREB in pancreatic beta -cells. Curr. Mol. Pharmacol. 2011, 4:187-195.
6. De Marinis Y.Z., Salehi A., Ward C.E., Zhang Q., Abdulkader F., Bengtsson M., Braha O., Braun M., Ramracheya R., Amisten S., Habib A.M., Moritoh Y., Zhang E., Reimann F., Rosengren A.H., Shibasaki T., Gribble F., Renstrom E., Seino S., Eliasson L., Rorsman P. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell. Metab. 2010, 11:543-553.
7. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiol. (Bethesda) 2009, 24:325-331.
8. Hamamoto S., Kanda Y., Shimoda M., Tatsumi F., Kohara K., Tawaramoto K., Hashiramoto M., Kaku K. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes. Metab. 2013, 15:153-163.
9. Hennige A.M., Burks D.J., Ozcan U., Kulkarni R.N., Ye J., Park S., Schubert M., Fisher T.L., Dow M.A., Leshan R., Zakaria M., Mossa-Basha M., White M.F. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J. Clin. Invest 2003, 112:1521-1532.
10. Kanda Y., Shimoda M., Hamamoto S., Tawaramoto K., Kawasaki F., Hashiramoto M., Nakashima K., Matsuki M., Kaku K. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E278-E286.
11. Kaneto H., Miyatsuka T., Kawamori D., Yamamoto K., Kato K., Shiraiwa T., Katakami N., Yamasaki Y., Matsuhisa M., Matsuoka T.A. PDX-1 and MafA play a crucial role in pancreatic beta-cell differentiation and maintenance of mature beta-cell function. Endocr. J. 2008, 55:235-252.
12. Kang Z.F., Deng Y., Zhou Y., Fan R.R., Chan J.C., Laybutt D.R., Luzuriaga J., Xu G. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. Diabetologia 2013, 56:423-433.
13. Kawasaki F., Matsuda M., Kanda Y., Inoue H., Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E510-E518.
14. Kawashima S., Matsuoka T.A., Kaneto H., Tochino Y., Kato K., Yamamoto K., Yamamoto T., Matsuhisa M., Shimomura I. Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem. Biophys. Res. Commun. 2011, 404:534-540.
15. Kendall D.M., Cuddihy R.M., Bergenstal R.M. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am. J. Med. 2009, 122:S37-S50.
16. Kim H.I., Ahn Y.H. Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes 2004, 53(Suppl. 1):S60-S65.
17. Kim H.I., Kim J.W., Kim S.H., Cha J.Y., Kim K.S., Ahn Y.H. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 2000, 49:1517-1524.
18. Kim H.I., Cha J.Y., Kim S.Y., Kim J.W., Roh K.J., Seong J.K., Lee N.T., Choi K.Y., Kim K.S., Ahn Y.H. Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 2002, 51:676-685.
19. Kim M.K., Kim H.S., Lee I.K., Park K.G. Endoplasmic reticulum stress and insulin biosynthesis: a review. Exp. Diabetes Res. 2012, 2012:509437.
20. Kitamura T., Kido Y., Nef S., Merenmies J., Parada L.F., Accili D. Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol. Cell. Biol. 2001, 21:5624-5630.
21. Kubota N., Tobe K., Terauchi Y., Eto K., Yamauchi T., Suzuki R., Tsubamoto Y., Komeda K., Nakano R., Miki H., Satoh S., Sekihara H., Sciacchitano S., Lesniak M., Aizawa S., Nagai R., Kimura S., Akanuma Y., Taylor S.I., Kadowaki T. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000, 49:1880-1889.
22. Kulkarni R.N., Bruning J.C., Winnay J.N., Postic C., Magnuson M.A., Kahn C.R. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999, 96:329-339.
23. Lambeir A.M., Durinx C., Scharpe S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40:209-294.
24. Lingohr M.K., Dickson L.M., McCuaig J.F., Hugl S.R., Twardzik D.R., Rhodes C.J. Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 2002, 51:966-976.
25. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur. J. Pharmacol. 2009, 602:448-454.
26. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br. J. Pharmacol. 2009, 157:415-426.
27. Park S., Dong X., Fisher T.L., Dunn S., Omer A.K., Weir G., White M.F. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 2006, 281:1159-1168.
28. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275:10761-10766.
29. Quan W., Lim Y.M., Lee M.S. Role of autophagy in diabetes and endoplasmic reticulum stress of pancreatic beta-cells. Exp. Mol. Med. 2012, 44:81-88.
30. Rafacho A., Cestari T.M., Taboga S.R., Boschero A.C., Bosqueiro J.R. High doses of dexamethasone induce increased beta-cell proliferation in pancreatic rat islets. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E681-E689.
31. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl. 1):S119-S124.
32. Roger B., Papin J., Vacher P., Raoux M., Mulot A., Dubois M., Kerr-Conte J., Voy B.H., Pattou F., Charpentier G., Jonas J.C., Moustaid-Moussa N., Lang J. Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells. Diabetologia 2011, 54:390-402.
33. Shimoda M., Kanda Y., Hamamoto S., Tawaramoto K., Hashiramoto M., Matsuki M., Kaku K. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011, 54:1098-1108.
34. Tamaki M., Fujitani Y., Uchida T., Hirose T., Kawamori R., Watada H. Combination treatment of db/db mice with exendin-4 and gastrin preserves beta-cell mass by stimulating beta-cell growth and differentiation. J. Diabetes Investig. 2010, 1:172-183.
35. Tarabra E., Pelengaris S., Khan M. A simple matter of life and death-the trials of postnatal Beta-cell mass regulation. Int. J. Endocrinol. 2012, 2012:516718.
36. Terauchi Y., Takamoto I., Kubota N., Matsui J., Suzuki R., Komeda K., Hara A., Toyoda Y., Miwa I., Aizawa S., Tsutsumi S., Tsubamoto Y., Hashimoto S., Eto K., Nakamura A., Noda M., Tobe K., Aburatani H., Nagai R., Kadowaki T. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J. Clin. Invest 2007, 117:246-257.
37. van Genugten R.E., van Raalte D.H., Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes. Metab. 2012, 14:101-111.
38. Withers D.J., Gutierrez J.S., Towery H., Burks D.J., Ren J.M., Previs S., Zhang Y., Bernal D., Pons S., Shulman G.I., Bonner-Weir S., White M.F. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998, 391:900-904.
39. Xu G., Kaneto H., Laybutt D.R., Duvivier-Kali V.F., Trivedi N., Suzuma K., King G.L., Weir G.C., Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007, 56:1551-1558.